Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 4,560 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: assessment only control Clear all

Conditions: Positive Parenting Skills
Interventions: Positive Parenting Seminar Series; Behavioral
Lead sponsor: Texas Tech University; Other
Eligibility: Not listed
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Cancer
Interventions: lapatinib, placebo matching lapatinib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Detroit, Michigan • Lebanon, New Hampshire • Durham, North Carolina + 1 more

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases
Interventions: FlorenceM, Medtronic insulin pump 640G; Device
Lead sponsor: University of Cambridge; Other
Eligibility: 6 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Aurora, Colorado • Minneapolis, Minnesota

Conditions: Child Obesity
Interventions: Parenting Mindfully for Health Nutrition (PMH), Contact Control Nutrition (C+N), Non-randomized historical control (WLC) assessment only; Behavioral · Other
Lead sponsor: Yale University; Other
Eligibility: 2 Years to 5 Years
Enrollment: 246 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hyperopia, Myopia
Interventions: 1% EXP039, Saline control; Drug · Other
Lead sponsor: Canyon City Eyecare; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Azusa, California

Conditions: Responsible Fatherhood
Interventions: Intervention - Responsible Fatherhood Programming; Other
Lead sponsor: Partnership for Maternal & Child Health of Northern New Jersey; Other
Eligibility: 18 Years and older · Male only
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Suicide Prevention
Interventions: PEACE, Standard Psychiatric Hospital Discharge Care; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: White River Junction, Vermont

Conditions: Mental Health
Interventions: Access to the SolanoConnex.org; Behavioral
Lead sponsor: Touro University, California; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Vallejo, California

Conditions: Influenza
Interventions: mRNA-1010, mRNA-1010.4, mRNA-1010.6; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 10
States / cities: Hollywood, Florida • Miami, Florida • Lenexa, Kansas + 7 more

Conditions: Contraception, Health Care Utilization
Interventions: Contraceptive Counseling; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 14 Years and older · Female only
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Total Occlusion of Coronary Artery
Interventions: NovaCross; Device
Lead sponsor: Nitiloop Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Little Rock, Arkansas • Naperville, Illinois • New York, New York + 1 more

Conditions: Obesity
Interventions: Behavioral weight loss intervention (Online; Rx Weight Loss), Minority stress intervention, Social support intervention, Negative body image intervention; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder
Interventions: Clinical Assessment Visit, fMRI scan; Diagnostic Test · Other
Lead sponsor: University of Michigan; Other
Eligibility: 6 Years to 18 Years
Enrollment: 256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Covid19
Interventions: COVI-AMG, Placebo; Biological · Drug
Lead sponsor: Sorrento Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 4
States / cities: Garden Grove, California • Bradenton, Florida • Miami, Florida + 1 more

Conditions: Diabetic Neuropathy
Interventions: JNJ-42160443 (1 mg), JNJ-42160443 (3 mg), JNJ-42160443 (10 mg), Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 23
States / cities: Jonesboro, Arkansas • Fresno, California • La Jolla, California + 20 more

Conditions: Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions: EDP-978, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: C-Section, Pain Management
Interventions: Exparel + Bupivacaine, Bupivacaine; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Loma Linda, California • Stanford, California • Boston, Massachusetts + 7 more

Conditions: Diabetic Macular Edema (DME)
Interventions: 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL); Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 59
States / cities: Scottsdale, Arizona • Encino, California • Fullerton, California + 52 more

Conditions: Acute Ischemic Stroke
Interventions: TAK-755, Placebo; Biological · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 6 more

Conditions: Influenza, Vaccine
Interventions: cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS); Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 39 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Durham, North Carolina • Cincinnati, Ohio

Conditions: GERD
Interventions: XP19986 CR, Placebo for XP19986 CR; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Stanford, California • Charleston, South Carolina • Tacoma, Washington

Conditions: Bunion, Hallux Valgus
Interventions: SKY0402, Placebo; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Brain Diseases, Spinal Cord Diseases
Interventions: Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), OptiMARK~0.1 mmol/kg BW; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 20
States / cities: Sacramento, California • San Diego, California • Jacksonville, Florida + 16 more

Conditions: Multiple Sclerosis, Healthy
Interventions: Not listed
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Search by objective public record fields.

Investigating a Brief Virtual Seminar Series for Parents of Children Ages 2-12

A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval

Home Testing of Day and Night Closed Loop With Pump Suspend Feature

Preventing Childhood Obesity Through a Mindfulness-Based Parent Stress Intervention

A Phase 1/2 Crossover Study to Assess EXP039 for Myopia or Hyperopia

Evaluation of the FELLAS Responsible Fatherhood Project

Suicide Prevention Study of VA-BIC in the Veteran Population

The SolanoConnex Trial: Evaluation of a Mental Health Access Project

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

Assessing Satisfaction With Contraceptive Counseling Using Telephone Versus Video Telehealth Visits

A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions

Optimizing an Online Behavioral Weight Loss Intervention and Novel Culturally Tailored Components for Sexual Minority Women

Study of Cognition and Control in Youths

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms

A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections

A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

A Study of TAK-755 in Adults With Acute Ischemic Stroke

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease

Study of Postoperative Analgesia in Bunionectomy

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis